IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis?

[1]  P. Rutgeerts,et al.  Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Deena J. Chisolm,et al.  Race Differences in Initial Presentation, Early Treatment, and 1-year Outcomes of Pediatric Crohn's Disease: Results from the ImproveCareNow Network. , 2016, Inflammatory bowel diseases.

[3]  C. Ponsioen,et al.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. , 2015, Gastroenterology.

[4]  Deena J. Chisolm,et al.  Racial Disparities in Readmission, Complications, and Procedures in Children with Crohn's Disease , 2015, Inflammatory bowel diseases.

[5]  C. Redmond,et al.  An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  G. Rogler,et al.  Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  W. Sandborn,et al.  Biologic Concentration Testing in Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.

[8]  W. Sandborn,et al.  Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study , 2014, Inflammatory bowel diseases.

[9]  D. Schwartz,et al.  Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study , 2014, Alimentary pharmacology & therapeutics.

[10]  M. Regueiro,et al.  Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops , 2014, Inflammatory bowel diseases.

[11]  C. Ruetsch,et al.  Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review. , 2014, American health & drug benefits.

[12]  P. Rutgeerts,et al.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. , 2014, Gastroenterology.

[13]  N. Abraham,et al.  Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  M. Silverberg,et al.  Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[15]  W. Sandborn,et al.  A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  C. Siegel,et al.  Do Inflammatory Bowel Disease Therapies Cause Cancer? , 2013, Inflammatory bowel diseases.

[17]  D. Mould,et al.  Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms , 2012, Clinical pharmacology and therapeutics.

[18]  R. Cross,et al.  Association of Age at Diagnosis and Ulcerative Colitis Phenotype , 2012, Digestive Diseases and Sciences.

[19]  A. Qureshi,et al.  Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients , 2011, The British journal of dermatology.

[20]  J. Inadomi,et al.  Race and Inflammatory Bowel Disease in an Urban Healthcare System , 2010, Digestive Diseases and Sciences.

[21]  A. Varol,et al.  The skin pathergy test: innately useful? , 2010, Archives of Dermatological Research.

[22]  J. Inadomi,et al.  Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis , 2010, Inflammatory bowel diseases.

[23]  A. Sonnenberg.  Temporal changes in the age distribution of inflammatory bowel disease hospitalization: data from England and Scotland , 2010, European journal of gastroenterology & hepatology.

[24]  A. Repaka,et al.  Crohn's Disease in an African-American Population , 2008, The American journal of the medical sciences.

[25]  G. Hatemi,et al.  Frequency of pathergy phenomenon and other features of Behçet's syndrome among patients with inflammatory bowel disease. , 2008, Clinical and experimental rheumatology.

[26]  S. Vermeire,et al.  The role of genetics in inflammatory bowel disease. , 2008, Current drug targets.

[27]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[28]  R. Cross,et al.  Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study , 2008, Inflammatory bowel diseases.

[29]  U. Broeckel,et al.  Pediatric inflammatory bowel disease: clinical and molecular genetics. , 2007, Inflammatory bowel diseases.

[30]  D. Hommes,et al.  Genetic susceptibility has a more important role in pediatric‐onset Crohn's disease than in adult‐onset Crohn's disease , 2007, Inflammatory bowel diseases.

[31]  A. Kornbluth,et al.  Do Black and Hispanic Americans With Inflammatory Bowel Disease (IBD) Receive Inferior Care Compared With White Americans? Uneasy Questions and Speculations , 2007, The American Journal of Gastroenterology.

[32]  K. Fiorino,et al.  Disease Presentation and Clinical Course in Black and White Children With Inflammatory Bowel Disease , 2007, Journal of pediatric gastroenterology and nutrition.

[33]  S. Hanauer.  Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". , 2007, Reviews in gastroenterological disorders.

[34]  William J. Tremaine,et al.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 , 2007, Inflammatory bowel diseases.

[35]  R. Cross,et al.  Racial differences in disease phenotypes in patients with Crohn's disease , 2006, Inflammatory bowel diseases.

[36]  M. Bala,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease , 2006 .

[37]  Dhiman Basu,et al.  Impact of Race and Ethnicity on Inflammatory Bowel Disease , 2005, The American Journal of Gastroenterology.

[38]  S. Galandiuk,et al.  Crohn’s Disease: Presentation and Severity Compared Between Black Patients and White Patients , 2005, Diseases of the colon and rectum.

[39]  H. Freeman.  Comparison of Longstanding Pediatric-Onset and Adult-Onset Crohn’s Disease , 2004, Journal of pediatric gastroenterology and nutrition.

[40]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[41]  S. Reddy,et al.  Inflammatory bowel disease in African Americans. , 2003, Inflammatory bowel diseases.

[42]  M. Regueiro,et al.  Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease , 2003, American Journal of Gastroenterology.

[43]  S. Hanauer,et al.  Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.

[44]  J. Callen,et al.  Clinical features and treatment of peristomal pyoderma gangrenosum. , 2000, JAMA.

[45]  R. Sandler,et al.  Crohn's disease: does race matter? , 2000, American Journal of Gastroenterology.

[46]  A. Fleischer,et al.  Pyoderma Gangrenosum A Comparison of Typical and Atypical Forms with an Emphasis on Time to Remission. Case Review of 86 Patients from 2 Institutions , 2000, Medicine.

[47]  B. Childs,et al.  Crohn's disease: influence of age at diagnosis on site and clinical type of disease. , 1996, Gastroenterology.

[48]  W. Su,et al.  Pyoderma gangrenosum: classification and management. , 1996, Journal of the American Academy of Dermatology.

[49]  C. Vadheim,et al.  Crohn's disease among ethnic groups in a large health maintenance organization. , 1992, Gastroenterology.

[50]  M. Cottone,et al.  Epidemiology of crohn's disease in Sicily: A hospital incidence study from 1987 to 1989 , 1991, European Journal of Epidemiology.

[51]  B. Schuman,et al.  Inflammatory Bowel Disease in 64 Black Patients: Analysis of Course, Complications, and Surgery , 1989, Journal of clinical gastroenterology.

[52]  W. Bergfeld,et al.  Pyoderma gangrenosum: a review. , 1988, Journal of the American Academy of Dermatology.

[53]  R. Macdermott,et al.  Clinical and operative experience with non-caucasian patients with Crohn's disease , 1986, Diseases of the colon and rectum.

[54]  A. Lilienfeld,et al.  Trends in incidence rates of ulcerative colitis and Crohn's disease , 1984, Digestive Diseases and Sciences.

[55]  J. Kirsner,et al.  The epidemiologic and demographic characteristics of inflammatory bowel disease: an analysis of a computerized file of 1400 patients. , 1971, Journal of chronic diseases.

[56]  A. Lilienfeld,et al.  Some epidemiological features of ulcerative colitis and regional enteritis. A preliminary report. , 1966, Gastroenterology.

[57]  E. Acheson.  On the mortality ascribed to ulcerative colitis. , 1959, Journal of chronic diseases.

[58]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.